2-Cycloheptylguanidine | 847572-30-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Cycloheptylguanidine
• CAS: 847572-30-9
• 化学式: C₈H₁₇N₃
• 分子量: 155.24
• InChiKey: KBKZNKAGGCOLFU-UHFFFAOYSA-N

物化性质

• 沸点：
  248.8±23.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Cycloheptylamine derivatives as anti-diabetic agents
  申请人：UNITED ARAB EMIRATES UNIVERSITY

  公开号：US11091426B1

  公开（公告）日：2021-08-17

  Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4′-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3′,5′-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1′-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2′-aminopyrimidin-4′-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3′-cycloheptylureido)-N-(5″-methylisoxazol-3″-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.

  环丙胺衍生物可用于预防或治疗人类、动物的疾病，并已经在治疗2型糖尿病方面表现出有效性。在一种实施方案中，环丙胺衍生物可以包括从环庚胺盐、环己胺盐、环戊胺盐、1-环庚基-[4,4′-联吡啶]-1-铵、N1,N2-环庚氧草酰胺、1-[3′,5′-双(三氟甲基)苯基]-3-环庚基脲、1,1′-(4-甲基-1,3-苯基)双(3-环庚基脲)、1-(2′-氨基嘧啶-4′-基)-3-环庚基脲、4-氨基-N-(环庚基氨基)苯磺酰胺、4-(3′-环庚基脲基)-N-(5″-甲基异噁唑-3″-基)苯磺酰胺、N-(环庚基氨基)-4-甲基苯磺酰胺、1-环庚基胍盐酸盐、(E)-氨基[(氨基(环庚基氨基)甲亚胺)氯化物]，或其药用可接受的盐。
• CYCLOHEPTYLAMINE DERIVATIVES AS ANTI-DIABETIC AGENTS
  申请人：United Arab Emirates University

  公开号：US20210347725A1

  公开（公告）日：2021-11-11

  Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4′-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3′,5′-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1′-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2′-aminopyrimidin-4′-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3′-cycloheptylureido)-N-(5″-methylisoxazol-3″-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.